Original ArticleNon–Small Cell Lung CancerCell-Free Plasma DNA-Guided Treatment With Osimertinib in Patients With Advanced EGFR-Mutated NSCLC
Keywords
Cited by (0)
Drs. Buder and Hochmair equally contributed to this work.
Disclosures: Dr. Buder has received personal fees from AstraZeneca. Dr. Bondalo has received personal fees from Boehringer Ingelheim, Eli Lilly, and Roche. Dr. Schenk has received personal fees from Actelion, AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, Celgene, Chiesi, Eli Lilly, Habel, Menarini, Merck Sharp & Dohme, Novartis, Otsuka, Pfizer, Roche, and Teva-Ratiopharm. Dr. Errhalt has received personal fees from AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, Chiesi, Eli Lilly, Merck Sharp & Dohme, Novartis, and Roche. Dr. Mikes has received personal fees from AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, Eli Lilly, Merck Sharp & Dohme, Novartis, Pfizer, and Roche. Dr. Absenger has received personal fees from AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, Celgene, Merck Sharp & Dohme, and Roche. Dr. Patocka has received personal fees from Actelion, Boehringer Ingelheim, Bristol-Myers Squibb, Eli Lilly, Pfizer, and Roche. Dr. Baumgartner has received personal fees from Boehringer Ingelheim, Eli Lilly, and Roche. Dr. Prosch has received personal fees from AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, Eli Lilly, Merck Sharp & Dohme, Novartis, and Roche. Dr. Pirker has received personal fees from AstraZeneca, Boehringer Ingelheim, and Clovis. Dr. Filipits has received personal fees from Astra Zeneca, Boehringer Ingelheim, Eli Lilly, Merck Sharp & Dohme, Novartis, Ratiopharm, and Roche. The remaining authors declare no conflicts of interest.